Valuation: Seres Therapeutics, Inc.

Market Cap 25.41M 22.7M 21.16M 19.18M 36.1M 2.41B 36.39M 253M 99.23M 1.25B 95.44M 93.35M 4.03B P/E 2026 *
-0.72x
P/E 2027 * -0.51x
Enterprise Value 25.41M 22.7M 21.16M 19.18M 36.1M 2.41B 36.39M 253M 99.23M 1.25B 95.44M 93.35M 4.03B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 92.9x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+1.38%
1 week-5.51%
Current month-23.28%
1 month-45.67%
3 months-51.83%
6 months-70.15%
Current year-82.73%
1 week 2.42
Extreme 2.42
2.78
1 month 2.42
Extreme 2.42
4.87
Current year 2.42
Extreme 2.42
16.42
1 year 2.42
Extreme 2.42
29.98
3 years 2.42
Extreme 2.42
41
5 years 2.42
Extreme 2.42
233.8
10 years 2.42
Extreme 2.42
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+1.38%-5.51%-86.95%-91.20% 25.41M
-2.01%-7.86%+54.60%+70.97% 70.44B
+3.84%-11.02%+8.59%+58.77% 50.31B
+3.35%+1.42%+11.85%+37.39% 47.51B
+0.79%+1.67%+28.15%+31.88% 42.91B
+3.41%-3.18%+309.45%+470.02% 40.39B
+1.24%-2.94%+10.09%+103.13% 39.69B
+0.06%-1.43%+10.47%+43.27% 30.59B
-2.95%-14.09%+37.94%+1.30% 26.8B
+0.01%-6.82%-13.51%-8.48% 22.36B
Average +0.90%-6.30%+37.07%+71.70% 37.1B
Weighted average by Cap. +0.95%-5.44%+53.85%+95.26%

Financials

2026 *2027 *
Net sales 13.8M 12.32M 11.49M 10.42M 19.6M 1.31B 19.75M 138M 53.87M 681M 51.82M 50.68M 2.19B 274K 244K 228K 206K 389K 25.96M 392K 2.73M 1.07M 13.5M 1.03M 1M 43.33M
Net income -37.49M -33.49M -31.21M -28.3M -53.26M -3.56B -53.68M -374M -146M -1.85B -141M -138M -5.94B -78.95M -70.53M -65.74M -59.6M -112M -7.49B -113M -788M -308M -3.9B -297M -290M -12.51B
Net Debt - -
Projected Income Statement - Annual - Seres Therapeutics, Inc.
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
14/10/26 US$2.570 +1.58% 6,027
13/10/26 US$2.530 -5.60% 44,061
12/10/26 US$2.680 -1.11% 54,279
09/10/26 US$2.710 +3.04% 79,411
08/10/26 US$2.630 -3.31% 213,360
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Seres Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.530USD
Average target price
17.00USD
Spread / Average Target
+571.94%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Seres Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MCRB Stock